english.prescrire.org > Spotlight > 100 most recent > Negative post-marketing trials: often ignored

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Negative post-marketing trials: often ignored

 Outlook  Accelerated or conditional marketing authorisation pathways are designed to speed up patient access to potential therapeutic advances. But when post­-marketing trials conducted to evaluate these drugs using clinical endpoints do not confirm the pre-authorisation trial results obtained using surrogate endpoints, drug regulatory agencies and the organisations responsible for cancer guidelines rarely take these negative results into account.
Full article available for download by subscribers

©Prescrire 1 December 2023

Source: "Negative post-marketing trials: often ignored" Prescrire Int 2023; 32 (254): 304-305. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Post-marketing studies
following conditional
authorisation: often lacking"
Prescrire Int 2023;
32 (254): 307.
Subscribers only

"Conditional marketing
authorisation: easier
to grant than to revoke"
Prescrire Int 2023;
32 (251): 223.
Free

"Early and compassionate
access to drugs in France"
Prescrire Int 2023;
32 (248): 136-137.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's Spotlight